All In Biotech

Drug Trial Radar · NCT03417388

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 2,476 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,476

Actual

Start

Feb 9, 2018

Primary completion

Feb 15, 2025

Study completion Apr 16, 2027

Sponsor

Lead sponsor
Cedars-Sinai Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United States Department of Defense; University of Florida
First posted
Jan 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Ischemia-IMT (Ischemia-Intensive Medical Treatment Reduces Events in Women with Non-Obstructive CAD), subtitle: Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR) trial is a multicenter, prospective, randomized, blinded outcome evaluation (PROBE design) evaluating intensive statin/ACE-I (or ARB)/aspirin treatment (IMT) vs. usual care (UC) in 4,422 symptomatic women patients with symptoms and/or signs of ischemia but no obstructive CAD. The hypothesis is that IMT will reduce major adverse coronary events (MACE) 20% vs. UC. The primary outcome is first occurrence of MACE as death, nonfatal MI, nonfatal stroke/transient ischemic attack (TIA) or hospitalization for heart failure or angina. Secondary outcomes include quality of life, time to "return to duty"/work, health resource consumption, angina, cardiovascular (CV) death and primary outcome components. Events will be adjudicated by an experienced Clinical Events Committee (CEC). Follow-up was planned to be 3-years using 50 sites: primarily VA and Active Duty Military Hospitals/Clinics and a National Patient-Centered Clinical Research Network (PCORnet) clinical data research network (CDRN)(OneFlorida Consortium). The number of sites were increased and follow up was modified to continue until the last patient enrolled was followed until trial follow up was completed. Recruitment was complete January 6, 2024. This study is being conducted to determine whether intensive medication treatment to modify risk factors and vascular function in women patients with coronary arteries showing no flow limit obstruction but with cardiac symptoms (i.e., chest pain, shortness of breath) will reduce the patient's likelihood of dying, having a heart attack, stroke/TIA or being hospitalized for cardiac reasons. The results will provide evidence data necessary to inform future guidelines regarding how best to treat this growing population of patients, and ultimately improve the patient's cardiac health and quality of life and reduce health-care costs.

Conditions

  • Coronary Artery Disease

Interventions

  • High dose potent statinDrug

    The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications.

  • ACE-I (lisinopril) or ARB (losartan)Drug

    Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension.

  • Aspirin 81 enteric coated tablet dailyDrug

    Will be recommended to IMT women without contraindications or bleeding risk.

  • Lifestyle CounselingBehavioral

    The PACE Lifestyle Assessment Intervention which is a program to assist with smoking cessation, weight loss, and exercise.

  • Quality of Life QuestionnairesBehavioral

    Quality of Life Questionnaires will be obtained.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary outcome is MACE, defined as first occurrence of all-cause death, non-fatal MI, non-fatal stroke, or hospitalization for angina or HF.Time frame: Within 5 years

Locations

81 sites in 2 countries. Site status is shown where the registry gives one.

  • Cardiology Associates of Mobile, Inc.

    Mobile, Alabama

  • Dignity Health-Mercy Gilbert Medical Center

    Gilbert, Arizona

  • Dignity Health-St. Joseph

    Phoenix, Arizona

  • University of Arizona

    Tucson, Arizona

  • University of Arkansas

    Little Rock, Arkansas

  • Cedars-Sinai Heart Institute

    Los Angeles, California

  • UCLA Medical Center

    Los Angeles, California

  • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center

    Torrance, California

  • Georgetown University

    Washington D.C., District of Columbia

  • Clearwater Cardiovascular Consultants Clinical Research

    Clearwater, Florida

  • South Palm Cardiovascular Research Institute

    Delray Beach, Florida

  • Family Medicine at Eastside Community Practice

    Gainesville, Florida

  • Family Medicine at Hampton Oaks Medical Plaza (Adults and Peds)

    Gainesville, Florida

  • Internal Medicine at Tower Hill

    Gainesville, Florida

  • Family Medicine at Haile Plantation (Adults & Peds)

    Gainesville, Florida

  • Malcom Randall VA Medical Center

    Gainesville, Florida

  • Cardiovascular Clinic at UF Health UF

    Gainesville, Florida

  • Internal Medicine at UF Health Medical Plaza

    Gainesville, Florida

  • Spring Hill Cardiology

    Gainesville, Florida

  • Family Medicine at 4th Ave

    Gainesville, Florida

  • Family Medicine at Old Town (Adults and Peds)

    Gainesville, Florida

  • Baptist Health

    Jacksonville, Florida

  • University of Florida, Jacksonville

    Jacksonville, Florida

  • Naval Hospital Jacksonville

    Jacksonville, Florida

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • UF Primary Care at Lake City SW

    Lake City, Florida

  • UF Primary Care at Lake City West

    Lake City, Florida

  • Charles H. Croft MDPA

    Melbourne, Florida

  • Daytona Heart Group

    Multiple Locations, Florida

  • Southwest Florida Research Institute

    Naples, Florida

  • Cardiovascular Instititute of Central Florida

    Ocala, Florida

  • Ocala Research Institute Inc.

    Ocala, Florida

  • Orlando Health

    Orlando, Florida

  • Naval Hospital Pensacola

    Pensacola, Florida

  • Cardiovascular Center of Sarasota

    Sarasota, Florida

  • Advent Sebring

    Sebring, Florida

  • James A. Haley Veterans Hospital

    Tampa, Florida

  • AdventHealth Tampa - Pepin Heart Institute

    Tampa, Florida

  • Interventional Cardiac Consultants

    Tampa, Florida

  • BayCare Medical Group

    Tampa, Florida

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.